Novo Nordisk Slashes Ozempic Price for Cash Customers, Wegovy Approved for Liver Disease

Wegovy Approval for Liver Disease

• 🚀 Wegovy, Novo Nordisk's weight-loss drug, has received approval to treat a liver disease known as MASH.
• 💡 This approval highlights the potential health benefits of weight-loss drugs beyond weight reduction, which can aid in securing insurance coverage.
• 🎯 The approval gives Novo Nordisk an edge over Eli Lilly, whose similar drugs are not yet approved for this specific liver condition.

Ozempic Price Reduction for Cash Customers

• 💰 Novo Nordisk is halving the price of Ozempic for cash-paying patients, making it available for $499 a month through its NovoCare pharmacy.
• 🤝 The company is also partnering with GoodRx to offer both Ozempic and Wegovy at this reduced price across US pharmacies.
• ⚠️ This move comes amid pressure on pharmaceutical companies to lower drug prices, though Novo Nordisk states the offer is unrelated to government discussions.

Ozempic vs. Wegovy and Drug Access

• ⚖️ Both Ozempic (diabetes) and Wegovy (weight loss) share the same active ingredient, semaglutide, with Wegovy being a higher-dose version.
• ❓ While the price cut aims to expand access, it remains to be seen how much impact it will have, as Ozempic is typically covered by insurance for type 2 diabetes treatment.
• 📈 Novo Nordisk's shares saw a significant gain following the announcement, and GoodRx's stock also surged due to the partnership.

Concerns About Compounded Drugs

• 🔬 The effectiveness of compounded versions of Ozempic and Wegovy, often offered by telehealth companies like Hims and Hers, is uncertain.
• 🧩 Unlike branded medications, compounded drugs do not undergo the same rigorous FDA approval process, meaning there are no studies proving their effectiveness.
• ⚠️ While some patients report weight loss and no significant new side effects from compounded drugs, there is a lack of visibility into their efficacy compared to branded medications.